Fairfax Media network navigation

  • Home
  • Shares
  • Share details

ANTISENSE THERAPEUTICS LIMITED (ANP)


Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Antisense Therapeutics Limited
Stock Code: ANP
Website: www.antisense.com.au
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 16
Equiv. Shares (M): 1,438

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.012 $ 0.011 $ 0.012 $ 0.011 $ 0.011 325,385 $ 0.001  9.091 %

Current Broker Consensus Recommendation more
Recommendation: Hold
Recommendation Date: 16th Nov 2009
12 Month Target Price (average): $0
Brokers Surveyed: 1

Company Overview

Business Description:
Antisense Therapeutics Limited (ANP) is a biopharmaceutical drug discovery and development company. ANP develops and commercialises second generation antisense pharmaceuticals for large unmet markets. ANP has four products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2012  A -1.8 -0.2 -- 0.0 0.0 0.0 --
2011  A -1.8 -0.2 -- 0.0 0.0 0.0 --
2010  A -3.4 -0.4 -- 0.0 0.0 0.0 --
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F
Acrux Limited (ACR) $593 M -0.8713 0.9685 0.7483 80.1802 40.7323 23.2984 0.0225 0.0211 0.0491
Antisense Therapeutics (ANP) $16 M -- -- -- -- -- -- 0.0000 -- --
Pharmaxis (PXS) $48 M -- -- -- -- -- -- 0.0000 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
ANP -- -- 2.62 -- --
Market 0.94 12.5 0.82 1.96 2.44
Sector 1.28 15.2 2.36 0.58 7.16

Directors
Name Position Start Date
Mr Robert William Moses Chairman 23 October 2001
Mr Mark P Diamond Managing Director 31 October 2001
Dr Christopher (Chris) Belyea Non-Executive Director 13 November 2000
Professor Graham Mitchell Non-Executive Director 24 October 2001

Management
Name Position
Phillip Hains Chief Financial Officer, Company Secretary
George Tachas Director, Drug Discovery & Patents

Substantial Shareholders
Holding Name
101,906,497 (7.09%) Polychip Pharmaceuticals Pty Ltd

Calendar of Events
Date Event
25 February 2014 Report (Interim)
01 October 2013 Report (Annual)
19 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Active Investing and Trading

An educational booklet with information on how analysis and risk management can enhance your share investments.

More details...

News

Investors positive ahead of Fed meeting

The Age 20/06/2013 | The sharemarket gained ground as investors took a cautiously optimistic stance before a keenly awaited update on economic stimulus measures in the United States.

Is New News a good news story?

The Age 20/06/2013 | Pre-split trading of shares in "New Newscorp," the print media-heavy spin-out from News Corp began quietly on Wednesday, and it will take a while to work out where the new vehicle is headed.

News Corp split has one company up, one company down

The Age 20/06/2013 | The two separately listed companies of News Corporation had a subdued first day of trading on the ASX before their demerger later this month.

Lehman's US arm pulls plug on $210m deal with investors

The Age 20/06/2013 | Local councils that lost millions on investments made through Lehman Brothers have suffered a major setback, after the US arm of the failed bank blocked a deal that would have delivered the investors up to $210 million.

Smart and skinny

The Age 20/06/2013 | China's Huawei has vowed to catch up with rivals Apple and Samsung as it unveiled its newest device — the Ascend P6, which it described as the world's thinnest smartphone.

Investors positive ahead of Fed meeting

Sydney Morning Herald 20/06/2013 | The sharemarket gained ground as investors took a cautiously optimistic stance before a keenly awaited update on economic stimulus measures in the United States.

More...

Sponsored Links
Feedback Form